Regulatory News has published 1 story about Cyllene Therapeutics on 20 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 20 September 2026.
This page is generated from Regulatory News’ editorial coverage of Cyllene Therapeutics. It is not an advertisement.
On the record
- Company
- Cyllene Therapeutics (formerly EG 427)
- Headquarters
- Paris, France
- Founded
- 2019, as EG 427, by Philippe Chambon with Alberto Epstein, François Giuliano, Pierre Denys and Charles Joussain
- Regulator
- U.S. Food and Drug Administration
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
